EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) is a GTP-dependent translation elongation factor that catalyzes aminoacyl-tRNA delivery to the ribosomal A-site during protein synthesis 1. Unlike the ubiquitously expressed EEF1A1, EEF1A2 replaces EEF1A1 in specialized tissues, suggesting tissue-specific translational regulation 1. Beyond canonical translation, EEF1A2 functions as a multitasking protein with non-canonical roles: it acts as a transcriptional cofactor in the hypoxia-induced circ-CDYL-EEF1A2 complex driving hepatocellular carcinoma lung metastasis 2, and serves as a tumor-suppressor in breast cancer by bridging PTEN, GSK3β, and the SCF ubiquitin ligase complex to promote Aurora kinase A degradation 3. EEF1A2 also regulates proteostasis under mitochondrial stress through PSMB9 expression 4. EEF1A2 displays context-dependent oncogenic properties: its lysine lactylation by KAT8 enhances translation and colorectal cancer tumorigenesis 5, while methylation by METTL13 promotes oncogenic function 3. Conversely, PTEN-bound eEF1A2 exhibits tumor-suppressive activity. Clinically, heterozygous EEF1A2 mutations cause developmental and epileptic encephalopathy 33 and intellectual developmental disorder 38 1, while its dysregulation associates with multiple solid tumors 6.